The Greater Cannabis Company, Inc. (GCAN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The Greater Cannabis Company, Inc. (GCAN) trades at $0.19 with AI Score 49/100 (Grade C). The Greater Cannabis Company, Inc. (GCAN) is focused on developing cannabinoid therapeutics, particularly through its oral transmucosal patch platform. Market cap: $183,365, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for GCAN: GCAN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GCAN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GCAN: the 1 perspectives are evenly split.
How is this calculated? →The Greater Cannabis Company, Inc. (GCAN) Healthcare & Pipeline Overview
The Greater Cannabis Company, Inc. (GCAN) specializes in cannabinoid therapeutics, leveraging an innovative oral transmucosal patch platform to deliver active compounds effectively, positioning itself within the evolving landscape of the healthcare industry.
What Is the Investment Thesis for GCAN?
The Greater Cannabis Company, Inc. presents a unique investment thesis centered on its innovative oral transmucosal patch platform for cannabinoid delivery. As the market for cannabinoid therapeutics continues to expand, driven by increasing legalization and acceptance, GCAN's focus on effective delivery methods positions it favorably. The company is poised to capitalize on the growing demand for alternative therapies, with the cannabinoid market projected to reach $56.7 billion by 2025. Key value drivers include the potential for partnerships with larger pharmaceutical companies and advancements in clinical research that could validate its products. However, investors should be aware of the regulatory landscape and the challenges associated with gaining FDA approval, which could impact timelines for commercialization and revenue generation.
Based on FMP financials and quantitative analysis
GCAN Key Highlights
- Market Cap: $0.00B, indicating a nascent stage of development.
- Free Cash Flow (FCF): $-0.00B, highlighting the need for capital to support growth initiatives.
- Beta: 0.38, suggesting lower volatility compared to the broader market.
- Dividend Yield: None, reflecting the company's focus on reinvestment rather than returning capital to shareholders.
- Employee Count: 1, indicating a lean operational structure.
Who Are GCAN's Competitors?
GCAN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GCAN's Key Strengths?
- Innovative delivery method for cannabinoid therapeutics.
- Focused approach on a niche market segment.
- Strong potential for growth in a rapidly expanding industry.
What Are GCAN's Weaknesses?
- Limited operational scale with only one employee.
- No current revenue generation, indicating financial vulnerability.
- Dependence on regulatory approvals for product commercialization.
What Could Drive GCAN Stock Higher?
- Potential partnerships with larger pharmaceutical companies to enhance research and distribution capabilities.
- Development of the oral transmucosal patch platform aimed at improving cannabinoid delivery.
- Increased research into cannabinoid benefits, potentially leading to new product offerings.
What Are the Key Risks for GCAN?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges in gaining FDA approval for cannabinoid products.
- Intense competition from established pharmaceutical companies in the cannabinoid market.
- Market volatility and changing public perception of cannabis affecting demand.
What Are the Growth Opportunities for GCAN?
- Growth opportunity 1: The global cannabinoid market is projected to reach $56.7 billion by 2025, driven by increasing legalization and acceptance of cannabis for medical use. The Greater Cannabis Company, Inc. can leverage its unique oral transmucosal patch platform to capture market share in this expanding sector, particularly as more states and countries implement favorable regulations.
- Growth opportunity 2: The increasing prevalence of chronic pain and other conditions that cannabinoids can address presents a significant growth opportunity. With a growing patient population seeking alternative therapies, GCAN's innovative delivery method can appeal to both patients and healthcare providers looking for effective solutions.
- Growth opportunity 3: Potential partnerships with larger pharmaceutical companies could enhance The Greater Cannabis Company’s research capabilities and market reach. Collaborations could lead to joint ventures that accelerate product development and commercialization timelines, tapping into established distribution networks.
- Growth opportunity 4: The ongoing research into the therapeutic benefits of cannabinoids, including their anti-inflammatory and analgesic properties, may result in new product development opportunities for GCAN. As clinical trials yield positive results, the company could expand its product offerings and enhance its market position.
- Growth opportunity 5: The trend towards personalized medicine is gaining traction in the healthcare industry. The Greater Cannabis Company can capitalize on this trend by developing tailored cannabinoid therapies that meet the specific needs of individual patients, thereby enhancing patient satisfaction and adherence.
What Opportunities Does GCAN Have?
- Expanding global cannabinoid market presents significant growth potential.
- Increasing research into cannabinoid benefits may lead to new product development.
- Potential for strategic partnerships with larger firms to enhance market reach.
What Threats Does GCAN Face?
- Regulatory challenges in gaining approval for cannabinoid products.
- Intense competition from established pharmaceutical companies.
- Market volatility and changing public perception of cannabis.
What Are GCAN's Competitive Advantages?
- Innovative oral transmucosal patch platform differentiates GCAN from competitors.
- Focus on research and development enhances product efficacy and patient outcomes.
- Small operational structure allows for agility and quick decision-making.
- Growing acceptance of cannabinoid therapies provides a favorable market environment.
- Potential for strategic partnerships with established pharmaceutical companies.
What Does GCAN Do?
The Greater Cannabis Company, Inc. was founded in 2014 and is headquartered in Baltimore, Maryland. The company is dedicated to the development and commercialization of cannabinoid therapeutics, focusing on innovative delivery methods that enhance the efficacy of cannabinoids. Its flagship product is an oral transmucosal patch platform that allows for the absorption of loaded actives through the buccal mucosa, providing a non-invasive and potentially more effective alternative to traditional methods of cannabinoid delivery. This approach not only aims to improve patient compliance but also seeks to optimize the therapeutic effects of cannabinoids. As a pioneer in this niche market, The Greater Cannabis Company is positioned to benefit from the growing acceptance and demand for cannabinoid-based therapies in the healthcare sector. The company operates in a rapidly evolving industry characterized by increasing research and development efforts, regulatory changes, and a broader acceptance of cannabis-derived products for medical use. Despite its small size, with only one employee, GCAN is focused on carving out a significant market presence by offering unique, scientifically-backed solutions to meet the needs of patients and healthcare providers alike.
What Products and Services Does GCAN Offer?
- Develops cannabinoid therapeutics focused on innovative delivery methods.
- Offers an oral transmucosal patch platform for cannabinoid delivery.
- Aims to enhance the efficacy of cannabinoids through non-invasive methods.
- Conducts research to support the therapeutic benefits of cannabinoids.
- Seeks to commercialize cannabinoid-based products for medical use.
- Operates within the healthcare sector, focusing on patient-centered solutions.
How Does GCAN Make Money?
- Generates revenue through the commercialization of cannabinoid therapeutics.
- Focuses on innovative product development to meet market demand.
- Explores partnerships with larger pharmaceutical companies for research and distribution.
- Utilizes a lean operational structure to minimize costs and maximize efficiency.
- Aims to capture market share in the growing cannabinoid therapeutics sector.
What Industry Does GCAN Operate In?
The drug manufacturing industry, particularly in the specialty and generic sectors, is experiencing significant growth as healthcare providers and patients increasingly recognize the therapeutic potential of cannabinoids. The market is projected to grow at a CAGR of 22.3% from 2021 to 2028, driven by rising demand for alternative treatment options and advancements in cannabinoid research. The competitive landscape includes established pharmaceutical companies and emerging biotech firms, all vying for a share of the lucrative cannabinoid market. The Greater Cannabis Company, with its focus on innovative delivery systems, aims to differentiate itself in this crowded space.
Who Are GCAN's Key Customers?
- Patients seeking alternative therapies for chronic conditions.
- Healthcare providers looking for effective cannabinoid-based treatments.
- Pharmaceutical companies interested in cannabinoid research and development.
- Investors looking for opportunities in the healthcare and biotech sectors.
- Regulatory bodies overseeing the approval of cannabinoid therapeutics.
Net buyingInsider Activity
The most recent 10 insider filings for The Greater Cannabis Company, Inc. break down as 4 sales and 6 purchases. On net that is roughly 101.1M shares acquired (about $917K) — insiders putting money in tends to read as conviction.
ROE 13%Key Financial Metrics
Return on equity for The Greater Cannabis Company, Inc. stands at 13.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -29.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
The Greater Cannabis Company, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
GCAN Valuation & Market Position
With a 183K market cap, The Greater Cannabis Company, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GCAN's quantitative score of 49/100 is below the peer average of 66/100.
GCAN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with many traders expressing optimism about upcoming product launches and market expansion.
- The cannabis sector is gaining traction, with increasing acceptance and regulatory developments favoring companies like GCAN.
- Social media discussions highlight a growing interest in cannabis investments, positioning GCAN as a potential leader in this evolving market.
Bear Case
- Concerns about regulatory hurdles persist, as ongoing changes in cannabis legislation can create uncertainty for companies operating in this space.
- Recent bearish sentiment on social platforms reflects skepticism about the company's ability to scale operations effectively amidst competition.
- Insider selling has raised flags among some investors, leading to doubts about the company's short-term outlook and financial health.
- Market perceptions remain cautious, as the cannabis industry faces scrutiny regarding profitability and sustainability, impacting investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GCAN Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Feb 11, 2020
GCAN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GCAN.
Price Targets
Wall Street price target analysis for GCAN.
GCAN MoonshotScore
What does this score mean?
The MoonshotScore rates GCAN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Aitan Zacharin
CEO
Aitan Zacharin has been leading The Greater Cannabis Company, Inc. since its inception in 2014. With a background in healthcare and business management, he has a deep understanding of the cannabinoid market and its therapeutic potential. His leadership is characterized by a commitment to innovation and patient-centered solutions.
Track Record: Under Aitan Zacharin's leadership, The Greater Cannabis Company has developed its unique oral transmucosal patch platform, positioning the company for future growth in the cannabinoid therapeutics market. His strategic vision has guided the company through its early stages of development.
GCAN OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB, often due to lower trading volumes or less stringent reporting standards. This tier can provide access to a wider range of investors but may also carry higher risks due to less oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may lead to uncertainty about the company's performance.
- Lower trading volumes can result in higher volatility and price fluctuations.
- Regulatory risks associated with the cannabis industry may impact operations.
- Verify the company's current financial health and operational status.
- Research the regulatory landscape affecting cannabinoid therapeutics.
- Assess the competitive landscape and potential market positioning.
- Evaluate the management team's experience and track record.
- Investigate any existing partnerships or collaborations.
- Established in 2014, indicating a degree of market presence.
- Focus on innovative therapeutic solutions in a growing industry.
- Leadership with relevant experience in healthcare and business.
The Greater Cannabis Company, Inc. Healthcare Stock: Key Questions Answered
What does The Greater Cannabis Company, Inc. do?
The Greater Cannabis Company, Inc. focuses on developing cannabinoid therapeutics, particularly through its innovative oral transmucosal patch platform. This platform allows for the effective delivery of cannabinoids, aiming to enhance patient compliance and therapeutic outcomes. The company operates within the healthcare sector, addressing the growing demand for alternative treatments.
What is The Greater Cannabis Company, Inc.'s drug pipeline status?
The Greater Cannabis Company, Inc. is currently in the early stages of developing its oral transmucosal patch platform. The company is focused on research and development to validate the therapeutic benefits of its products. As the regulatory landscape evolves, the company aims to advance its pipeline towards commercialization, depending on successful research outcomes and regulatory approvals.
What are the main risks for GCAN?
The main risks for The Greater Cannabis Company, Inc. include regulatory challenges associated with gaining FDA approval for its cannabinoid products, which could delay commercialization. Additionally, the company faces ongoing competition from established pharmaceutical firms, which may impact its market entry and growth. Market volatility and changing public perception of cannabis could also affect demand for its products.
What are the key factors to evaluate for GCAN?
The Greater Cannabis Company, Inc. (GCAN) holds an AI score of 49/100 (low). Not financial advice.
How frequently does GCAN data refresh on this page?
GCAN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GCAN's recent stock price performance?
The Greater Cannabis Company, Inc. (GCAN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative delivery method for cannabinoid therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GCAN overvalued or undervalued right now?
Valuing The Greater Cannabis Company, Inc. (GCAN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GCAN?
Before investing in The Greater Cannabis Company, Inc. (GCAN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited operational scale and financial disclosures may affect investment decisions.